Since AURKA-specific inhibitors show poor efficacy and a high degree of toxicity in clinical trials [29], the available inhibitors against Complex V functions [38] could be a valuable resource for combinatorial therapies against AURKA and ATP5F1A or ATP5F1B in AURKA-related cancers in the upcoming future. Here, ATP5F1A is linked to cancer.